Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01537549 · ClinicalTrials.gov registry record · Phase 1
Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01537549 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 11 participants.
The verdict
NCT01537549, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some neuroprotective activities and it is hoped that they could be helpful for people with neurodegenerative illnesses such as progressive supranuclear palsy (PSP). The purpose of this study is to find out whether the nutritional supplement alpha-lipoic acid/L-acetyl carnitine is safe and well-tolerated in individuals with PSP when given daily, and whether it affects their well-being, brain scan measurements and blood tests that measure the energy metabolism in cells.
Interventions
- DRUG alpha-lipoic acid and L-acetyl carnitine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-09-14 |
| Est. Completion | 2015-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01537549
The ClinicalTrials.gov registry entry for NCT01537549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alpha-lipoic acid and L-acetyl carnitine is the first listed.
NCT01537549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01537549 about?
NCT01537549 is a clinical study titled "Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy". Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some neuroprotective activities and it is hoped that they could be helpful for people with neurodegenerative illnesses such as progressive supranuclear palsy (PSP). The purpose of this study is to find out whether the nutriti...
What is the current status of trial NCT01537549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-09-14. Estimated completion is 2015-04-07.
What interventions are being tested in trial NCT01537549?
The interventions under investigation include: alpha-lipoic acid and L-acetyl carnitine (DRUG).
Who is sponsoring clinical trial NCT01537549?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.